Barclays Issues Positive Forecast for Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price

Iovance Biotherapeutics (NASDAQ:IOVA) had its price objective lifted by analysts at Barclays from $18.00 to $19.00 in a report issued on Friday, Benzinga reports. The brokerage presently has an “overweight” rating on the biotechnology company’s stock. Barclays‘s price objective would indicate a potential upside of 143.00% from the stock’s previous close.

Several other brokerages have also issued reports on IOVA. The Goldman Sachs Group started coverage on Iovance Biotherapeutics in a research report on Thursday, September 24th. They set a “buy” rating and a $15.00 target price for the company. Robert W. Baird upped their target price on Iovance Biotherapeutics from $6.00 to $11.00 and gave the company a “neutral” rating in a research note on Thursday, October 8th. TD Cowen lifted their price objective on shares of Iovance Biotherapeutics from $7.00 to $10.00 and gave the company a “buy” rating in a research note on Monday, August 24th. Wells Fargo & Company upped their price objective on shares of Iovance Biotherapeutics from $14.00 to $18.00 and gave the company an “overweight” rating in a report on Wednesday, September 30th. Finally, Citizens Jmp upped their price objective on shares of Iovance Biotherapeutics from $8.00 to $12.00 and gave the company a “market outperform” rating in a report on Friday. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Iovance Biotherapeutics has a consensus rating of “Moderate Buy” and an average target price of $13.80.

Iovance Biotherapeutics Price Performance

Shares of Iovance Biotherapeutics stock traded up $0.08 during trading on Friday, hitting $7.82. The stock had a trading volume of 3,440,369 shares, compared to its average volume of 15,785,990. Iovance Biotherapeutics has a 12 month low of $2.08 and a 12 month high of $15.37. The firm’s fifty day simple moving average is $11.38 and its 200-day simple moving average is $5.94. The stock has a market cap of $3.54 billion, a PE ratio of -10.69 and a beta of 0.88.

Iovance Biotherapeutics (NASDAQ:IOVA) last issued its quarterly earnings results on Thursday, November 5th. The biotechnology company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.04. Iovance Biotherapeutics had a negative net margin of 89.11% and a negative return on equity of 40.51%. The company had revenue of $121.47 million for the quarter, compared to the consensus estimate of $115.98 million. The firm’s revenue was up 64.8% compared to the same quarter last year. Analysts expect that Iovance Biotherapeutics will post -0.45 earnings per share for the current fiscal year.

Institutional Trading of Iovance Biotherapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Brighton Jones LLC raised its position in shares of Iovance Biotherapeutics by 5.1% in the third quarter. Brighton Jones LLC now owns 40,069 shares of the biotechnology company’s stock worth $594,000 after acquiring an additional 1,954 shares during the period. Pictet Asset Management Holding SA boosted its stake in shares of Iovance Biotherapeutics by 867.6% during the 3rd quarter. Pictet Asset Management Holding SA now owns 416,539 shares of the biotechnology company’s stock worth $6,043,000 after acquiring an additional 373,491 shares in the last quarter. Kestra Advisory Services LLC boosted its stake in shares of Iovance Biotherapeutics by 25.2% during the 3rd quarter. Kestra Advisory Services LLC now owns 42,150 shares of the biotechnology company’s stock worth $625,000 after acquiring an additional 8,483 shares in the last quarter. Pathway Financial Advisers LLC acquired a new stake in shares of Iovance Biotherapeutics during the 3rd quarter valued at about $427,000. Finally, Compass Financial Management LLC acquired a new stake in shares of Iovance Biotherapeutics during the 3rd quarter valued at about $37,000. Institutional investors and hedge funds own 77.03% of the company’s stock.

Key Stories Impacting Iovance Biotherapeutics

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Q3 results topped expectations. Iovance reported about $122 million in revenue, a record, and a loss of $0.05 per share versus the $0.09 loss analysts expected. Amtagvi sales drove growth, gross margin rose to about 60%, and lower R&D costs helped improve results. The company reaffirmed its 2026 revenue outlook. Article: IOVA Q3 Earnings Beat on Amtagvi Sales and Lower R&D Costs
• Positive Sentiment: Sarcoma program gained regulatory momentum. Lifileucel received FDA Fast Track designation following strong sarcoma trial data. Iovance also reported a 55.6% response rate in UPS and DDLPS, with a registrational trial underway. Article: Iovance Biotherapeutics Lifileucel Wins Fast Track After Strong Sarcoma Trial Data
• Neutral Sentiment: An analyst upgraded the stock to Buy after resetting expectations, citing momentum in the Amtagvi melanoma launch. The analyst also cautioned that the opportunity in lung cancer may have been overestimated. Article: Iovance: Reset Expectations Make The Stock a Buy Again
• Negative Sentiment: Lung-cancer data remain a risk. Lifileucel showed a 24.6% response rate across 69 evaluable non-squamous NSCLC patients, slightly below an earlier interim result. The reported 59.1% response rate in a biomarker-selected subgroup is more encouraging, but the treatment’s broader potential remains uncertain. Article: Iovance Reports Q3 2026 Results and Updates

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc (NASDAQ: IOVA) is a biotechnology company focused on developing and commercializing personalized cell therapies for patients with cancer. Its technology is based on tumor-infiltrating lymphocytes (TILs), immune cells collected from a patient’s tumor, expanded outside the body, and reinfused to help attack cancer cells.

The company’s lead product, Amtagvi (lifileucel), is an autologous TIL therapy approved in the United States for certain adults with unresectable or metastatic melanoma that has progressed following prior treatment.